Continuous-flow left ventricular assist devices associated survival awaiting heart and heart-kidney transplant.

Autor: Weber MP; Division of Cardiac Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., O'Malley TJ; Division of Cardiac Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Maynes EJ; Division of Cardiac Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Choi JH; Division of Cardiac Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Morris RJ; Division of Cardiac Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Massey HT; Division of Cardiac Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA., Tchantchaleishvili V; Division of Cardiac Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Jazyk: angličtina
Zdroj: Artificial organs [Artif Organs] 2023 Apr; Vol. 47 (4), pp. 770-776. Date of Electronic Publication: 2022 Dec 30.
DOI: 10.1111/aor.14473
Abstrakt: Background: Improvement in continuous-flow left ventricular assist device (CF-LVAD) technology has translated to better outcomes for patients on CF-LVAD support as a bridge-to-transplant. However, data are lacking regarding the subset of CF-LVAD patients with renal failure awaiting simultaneous heart-kidney transplant (HKTx). We sought to better understand the characteristics and outcomes of patients in this group.
Methods: The United Network for Organ Sharing (UNOS) database was used to identify adult patients listed for heart transplant (HTx) or HKTx from January 1, 2009 to March 31, 2017. Patients were followed from time on waitlist to either removal from waitlist or transplantation. Demographic and clinical data for HTx and HKTx patients were assessed. Kaplan-Meier analysis assessed waitlist and post-transplant survival. For waitlisted patients, both death and removal from the waitlist due to deteriorating medical condition were considered events.
Results: Overall, 26 638 patients registered for transplant were analyzed. 25 111 (94%) were listed for HTx, and 1527 (6%) for HKTx. 7683 (29%) patients listed for HTx had CF-LVAD support. For those listed for HKTx, 441 (28%) underwent dialysis alone, 256 (17%) had CF-LVAD support alone, and 85 (6%) were treated with both CF-LVAD and dialysis. 15 567 (58%) underwent HTx, and 621 (2%) underwent HKTx. In these groups, post-transplant survival was similar (p = 0.06). Patients listed for HKTx treated with both dialysis and CF-LVAD had significantly worse waitlist survival compared to HKTx recipients (p < 0.001).
Conclusion: Post-transplant survival is comparable between HTx and HKTx, and early survival is similar between HTx patients and those listed for HTx with CF-LVAD support. However, outcomes on the waitlist for HKTx in CF-LVAD patients on dialysis is significantly worse compared to HKTx recipients. This highlights the need to better account for this patient population when allocating organs.
(© 2022 International Center for Artificial Organ and Transplantation (ICAOT) and Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje